Cargando…

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data

BACKGROUND AND OBJECTIVES: The pharmacokinetics of polyethylene glycol-conjugated asparaginase (PEG-ASNase) are characterized by an increase in elimination over time, a marked increase in ASNase activity levels from induction to reinduction, and high inter- and intraindividual variability. A populat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Würthwein, Gudrun, Lanvers-Kaminsky, Claudia, Siebel, Christian, Gerß, Joachim, Möricke, Anja, Zimmermann, Martin, Stary, Jan, Smisek, Petr, Schrappe, Martin, Rizzari, Carmelo, Zucchetti, Massimo, Hempel, Georg, Wicha, Sebastian G., Boos, Joachim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935823/ https://www.ncbi.nlm.nih.gov/pubmed/33595793 http://dx.doi.org/10.1007/s13318-021-00670-8

Ejemplares similares

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia
por: Khalil, Alaeddin, et al.
Publicado: (2020)

Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach
por: Siebel, Christian, et al.
Publicado: (2021)

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
por: Rizzari, Carmelo, et al.
Publicado: (2019)

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
por: Rizzari, Carmelo, et al.
Publicado: (2023)

Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring
por: Siebel, Christian, et al.
Publicado: (2020)

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
por: Möricke, Anja, et al.
Publicado: (2023)

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia
por: Avramis, Vassilios I, et al.
Publicado: (2006)

Asparaginase pharmacokinetics and implications of therapeutic drug monitoring
por: Asselin, Barbara, et al.
Publicado: (2015)

Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure
por: Siebel, Christian, et al.
Publicado: (2020)

Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion
por: Baruchel, André, et al.
Publicado: (2020)

Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi
por: Tong, Wing H., et al.
Publicado: (2023)

Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia
por: Heilmann, Janina, et al.
Publicado: (2023)

Novel site-specific PEGylated L-asparaginase
por: Meneguetti, Giovanna Pastore, et al.
Publicado: (2019)

Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment
por: Rizzari, Carmelo, et al.
Publicado: (2014)

Correction: Novel site-specific PEGylated L-asparaginase
por: Meneguetti, Giovanna Pastore, et al.
Publicado: (2019)

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
por: Patel, B, et al.
Publicado: (2017)

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019)

Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian Center
por: Cecconello, Daiane Keller, et al.
Publicado: (2020)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia
por: Nielsen, Rikke L., et al.
Publicado: (2022)

Acute lymphoblastic leukemia
por: Schrappe, Martin
Publicado: (2018)

P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE
por: Agustina Perusini, Maria, et al.
Publicado: (2023)

The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia
por: Lühmann, Jonathan Lukas, et al.
Publicado: (2021)

L-Asparaginase induced thrombosis in acute lymphoblastic leukemia
por: Kulkarni, Ketan P.
Publicado: (2012)

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
por: Hijiya, Nobuko, et al.
Publicado: (2016)

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
por: Egler, Rachel A., et al.
Publicado: (2016)

PTEN/PI3K/Akt pathway alters sensitivity of T-cell acute lymphoblastic leukemia to l-asparaginase
por: Hlozkova, Katerina, et al.
Publicado: (2022)

National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
por: Lussana, Federico, et al.
Publicado: (2020)

Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP‐BFM acute lymphoblastic leukemia protocol
por: Jung, Mareike, et al.
Publicado: (2020)

Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia
por: M'harzi, Soulaimane, et al.
Publicado: (2022)

Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases
por: Müller, Judit, et al.
Publicado: (2023)

Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management
por: Talamo, Laura, et al.
Publicado: (2017)

PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review
por: Medawar, Camile Valle, et al.
Publicado: (2020)

Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase
por: Modi, Tapasvi, et al.
Publicado: (2021)

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli‐Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia
por: Vrooman, Lynda M., et al.
Publicado: (2015)

L-asparaginase-induced Parotitis in an Elderly Patient with Acute Lymphoblastic Leukemia
por: Saburi, Masuho, et al.
Publicado: (2020)

L-Asparaginase Toxicity in the Treatment of Children and Adolescents with Acute Lymphoblastic Leukemia
por: Schmidt, Madalina-Petronela, et al.
Publicado: (2021)

PB1739: ADVERSE EFFECTS OF ASPARAGINASE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
por: Chenbah, Wafa, et al.
Publicado: (2023)

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kim, Hyun Jee, et al.
Publicado: (2018)

Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis
por: Dai, Zhan-Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vumfd6frpds3efcrda9oo4p9p3